| Document Date: 2009-07-16 17:32:35
Open Document File Size: 2,85 MBShare Result on Facebook
Company Sharp / RNAi Discovery / Ribopharma AG. / Alnylam Europe AG / Alnylam Pharmaceuticals Inc. / Roche Kulmbach AG / Tuschl / / Country Germany / United States / / Event Person Travel / Man-Made Disaster / Patent Filing / / Facility Carnegie Institute / Plant Cell / Whitehead Institute / University of Bayreuth / RISC complex / Max Planck Institute / / IndustryTerm mammalian systems / large pharmaceutical / chemical modifications / / MedicalCondition cancer / HIV / disease / Huntington’s disease / HCV / diseases / hypercholesterolemia / Human Disease / / MedicalTreatment chemotherapy / / Organization Whitehead Institute / Carnegie Institute / University of Bayreuth / MIT / Max Planck Institute / European Union / / Person Stefan Limmer / Thomas Tuschl / Andrew Fire / Craig Mello / Roland Kreutzer / Max Planck (Garching) / / Position designer / MP / messenger / target messenger / / Product RNAi PRIMER The / RNAi PRIMER / RNAi PRIMER Key Milestones / / PublishedMedium the journal Nature / / Technology drug discovery / antibodies / siRNA / gene expression / chemotherapy / cell signaling / Drug Development / /
SocialTag |
Contents An Introduction to RNA Interference (RNAi) and Drug Development 4